World Conference on Lung Cancer | Conference

Lurbinectedin/Irinotecan Shows Impressive Antitumor Activity in Relapsed SCLC

February 15th 2021

February 15, 2021 - The combination of lurbinectedin and irinotecan following relapse on frontline treatment was found to induce promising antitumor activity in patients with small cell lung cancer.

Pembrolizumab Continues to Improve Survival in PD-L1–Positive Advanced NSCLC

January 28th 2021

January 28, 2021 - Pembrolizumab continued to demonstrate a clinically meaningful improvement in overall and progression-free survival, compared with docetaxel, in patients with previously treated, PD-L1–positive advanced non-small cell lung cancer after more than 5 years of follow-up.

Apatinib Plus Chemotherapy Shows Promising Efficacy, Tolerability in Pretreated SCLC

January 28th 2021

January 28, 2021 - The addition of apatinib to single agent chemotherapy showed promising efficacy and was found to be well tolerated in patients with pretreated advanced small cell lung cancer.

Sintilimab/Pemetrexed Regimen Significantly Improves PFS in Advanced NSCLC

August 8th 2020

Sintilimab injection plus pemetrexed and platinum-based therapy led to a statistically significant improvement in progression-free survival compared with chemotherapy alone as a first-line treatment for patients with locally advanced or metastatic nonsquamous non–small cell lung cancer.

Osimertinib Produces High Response Rate in EGFR T790M-Mutant NSCLC

September 10th 2015

The third-generation TKI osimertinib (AZD9291) showed a 71% objective response rate in patients with EGFR T790M-mutant non–small cell lung cancer following resistance to frontline anti-EGFR therapy.

Deep Sequencing Reveals Possible Primary Resistance Mechanism in EGFR-Mutant NSCLC

September 9th 2015

Coexisting driver mutations in EGFR-mutant non–small cell lung cancer could potentially contribute to primary resistance to EGFR-targeted therapy.

Cetuximab Improves Survival in EGFR-Positive Squamous NSCLC

September 9th 2015

The addition of cetuximab (Erbitux) to chemotherapy reduced the risk of death by 44% for patients with advanced squamous non–small cell lung cancer whose tumors test positive for EGFR gene amplification.

Survival Not Improved by Adjuvant Bevacizumab in NSCLC

September 9th 2015

The addition of bevacizumab (Avastin) to adjuvant chemotherapy did not improve overall survival in patients with surgically resected early-stage non–small cell lung cancer.

Survival Trends Higher With Necitumumab in EGFR FISH-Positive Squamous NSCLC

September 9th 2015

Survival for patients with metastatic squamous non–small cell lung cancer whose tumors were positive for EGFR copy number as determined by FISH analysis tended to be better when the EGFR antibody necitumumab was added to their conventional chemotherapy.

Potential Role Revealed for EGFR Inhibition Beyond Progression in NSCLC

September 9th 2015

Continued treatment with gefitinib beyond progression exhibited a trend toward better outcomes in patients with T790M-negative non­–small cell lung cancer.

Dr. Bauml on a New Platform to Enhance Lung Cancer Clinical Trial Enrollment

September 9th 2015

Joshua M. Bauml, MD, assistant professor, University of Pennsylvania, discusses a novel IT platform designed to enhance lung cancer clinical trial enrollment.

Dr. Pelosof on the Increasing Incidence of Never Smokers in NSCLC

September 9th 2015

Lorraine Pelosof, MD, PhD, from The University of Texas Southwestern Medical Center, discusses a study looking at the incidence of never smokers diagnosed with non-small cell lung cancer (NSCLC).

Dr. Jänne on Biomarker Results From a Study of AZD9291

September 9th 2015

Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, discusses biomarker results from the AURA study of AZD9291.

Dr. Gitlitz Discusses the Genomics of Young Lung Cancer Study

September 9th 2015

Barbara J. Gitlitz, MD, from the University of Southern California, discusses results and key takeaways from The Genomics of Young Lung Cancer Study.

Nivolumab/Ipilimumab Combination Active in Advanced NSCLC

September 8th 2015

A chemotherapy-free regimen of nivolumab and ipilimumab demonstrated activity as a first-line therapy for patients with advanced non–small cell lung cancer.

Nivolumab Survival Benefit Sustained in Squamous NSCLC

September 8th 2015

Treatment with the PD-1 inhibitor nivolumab demonstrated a 32% reduction in the risk of death compared with docetaxel for patients with previously treated squamous non–small cell lung cancer.

Actionable Mutations Common in Young Lung Cancer Patients

September 8th 2015

Most patients younger than age 40 with lung cancer had tumors with mutations that can be targeted with existing therapies.

Bevacizumab Triplet Improves Survival in Mesothelioma

September 8th 2015

Adding bevacizumab (Avastin) to a standard chemotherapy doublet reduced the risk of death by 24% and disease progression by 39% in patients with malignant pleural mesothelioma.

Dr. Govindan on the Genomic Characterization of Large-Cell Neuroendocrine Lung Tumors

September 7th 2015

Ramaswamy Govindan, MD, medical oncologist, Washington University School of Medicine in St. Louis, discusses a talk given at the 16th World Conference on Lung Cancer.

Atezolizumab Plus Chemo Leads to High Response Rate in NSCLC

September 7th 2015

Patients with newly diagnosed metastatic non-small lung cancer had double the expected response when the PD-L1 inhibitor atezolizumab was added to chemotherapy.

NEXT PAGE
PREVIOUS PAGE